In vitro and in vivo effects of quinupristin-dalfopristin against pneumocystis carinii

Antimicrobial Agents and Chemotherapy

Volumn 45, Issue 11, 2001, Pages 3234-3237

  Walzer, P D ^a   Ashbaugh, A ^a   Collins, M ^a   Cushion, M T ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DALFOPRISTIN PLUS QUINUPRISTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC PROPHYLAXIS; ARTICLE; BACTERIUM CULTURE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; IC 50; IMMUNE DEFICIENCY; MOUSE; NONHUMAN; PNEUMOCYSTIS CARINII; PRIORITY JOURNAL;

ADENOSINE TRIPHOSPHATE; ANIMALS; ANTI-BACTERIAL AGENTS; INJECTIONS, INTRAPERITONEAL; MICE; MICE, INBRED C3H; MICROBIAL SENSITIVITY TESTS; PNEUMOCYSTIS; PNEUMOCYSTIS INFECTIONS; VIRGINIAMYCIN;

EID: 0034775106     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.45.11.3234-3237.2001     Document Type: Article

References (32)

1. Pneumocystis carinii is resistant to imidazole antifungal agents
2. A review of the in-vitro activity of quinupristin/dalfopristin against intracellular pathogens and mycoplasmas
3. The pharmacokinetics of quinupristin/dalfopristin in laboratory animals and in humans
4. Bacterial activity and kinetics of RP 59500 in a mouse model of Staphylococcus aureus septicaemia
5. Quinupristin-dalfopristin
6. Quinupristin/dalfopristin: A review of its activity in experimental animal models of infection
7. Pharmacodynamics of macrolides, azalides, and streptogramins: Effect on extracellular pathogens
8. Use of an ATP bioluminescent assay to evaluate viability of Pneumocystis carinii from rats
9. Effect of atovaquone and atovaquone drug combinations on prophylaxis of Pneumocystis carinii pneumonia in SCID mice Antimicrob
10. Employment of terbinafine against Pneumocystis carinii infection in rat models
11. Activity of terbinafine against Pneumocystis carinii in vitro and its efficacy in the treatment of experimental pneumonia
12. A cytotoxicity assay for evaluation of candidate anti-Pneumocystis carinii agents
13. Effects of atovaquone and diospyrin-based drugs on the cellular ATP of Pneumocystis carinii f. sp. carinii
14. Cellular uptake and intracellular bactericidal activity of RP 59500 in murine macrophages
15. In vitro activity, of quinupristin/dalfopristin (Synercid, RP 59500) against Legionella spp.
16. Treatment of infection due to Pneumocystis carinii
17. Inhibitors of sterol biosynthesis and amphotericin B reduce the viability of Pneumocystis carinii f. sp. carinil
18. Pneumocystis carinii mutations are associated with duration of sulfa or sulfone prophylaxis exposure in AIDS patients
19. Quinupristin-dalfopristin is active against Toxoplasma gondii
20. Effect of quinupristin/dalfopristin on production of cytokines by human monocytes
21. Quinupristin/dalfopristin: A review of its use in the management of serious gram-positive infections
22. Efficacy of Mk-991 (L-743,872), a semisynthetic pneumocandin, in murine models of Pneurnocystis carinii
23. New semisynthetic pneumocandins with improved efficacies against Pneumocystis carinii in the rat
24. Genomic organization of signal transduction genes surrounding a putative 7-transmembrane pheromone receptor of Pneurnocystis carinii f. sp. carinii
25. 24(25) sterol methyltransferase block sterol synthesis and cell proliferation in Pneumocystis carinii
26. Sequence polymorphisms in the Pneumocystis carinii cytochrome b gene and their association with atovaquone prophylaxis failure
27. Pneumocystis carinii
28. Guanylhydrazones in treatment of Pneurnocystis carinii pneumonia in immunosuppressed rats
29. Treatment of experimental pneumocystosis: Review of seven years of experience and development of a new system for classifying antimicrobial drugs
30. Clinically used antimicrobial drugs against experimental pneumocystosis singly and in combination: Analysis of drug interactions and efficacies
31. Immunodeficient and immunosuppressed mice as models to test anti-Pneumocystis carinii drugs
32. Anti-human immunodeficiency virus drugs are ineffective against Pneumocystis carinii in vitro and in vivo